The Emperor's New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration

  title={The Emperor's New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration},
  author={Irving Kirsch and Thomas J. Moore and Alan Scoboria and Sarah S. Nicholls},
  journal={Prevention \& Treatment},
This article reports an analysis of the efficacy data submitted to the U.S. Food and Drug Administration for approval of the 6 most widely prescribed antidepressants approved between 1987 and 1999. [] Key Result Approximately 80% of the response to medication was duplicated in placebo control groups, and the mean difference between drug and placebo was approximately 2 points on the 17-item (50-point) and 21-item (62-point) Hamilton Depression Scale.

Figures and Tables from this paper

Antidepressants and the placebo response
  • I. Kirsch
  • Medicine, Psychology
    Epidemiology and Psychiatric Sciences
  • 2009
Because they do not incur drug risks, exercise and psychotherapy, which show at benefits at least equal to those of antidepressants, may be a better treatment choice for depressed individuals.
The potency of these antidepressants was ‘small and of questionable clinical value’ and ‘the placebo component of the response to [antidepressant] medication is considerably greater than the pharmacological effect’.
The emperor's new drugs: medication and placebo in the treatment of depression.
  • I. Kirsch
  • Psychology
    Handbook of experimental pharmacology
  • 2014
Analysis of the published data and the unpublished data that were hidden by the drug companies reveal that most (if not all) of the benefits are due to the placebo effect.
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Drug–placebo differences in antidepressant efficacy increase as a function of baseline severity, but are relatively small even for severely depressed patients.
Placebo Effect in the Treatment of Depression and Anxiety
  • I. Kirsch
  • Psychology, Medicine
    Front. Psychiatry
  • 2019
Analysis of the published and the unpublished clinical trial data are consistent in showing that most (if not all) of the benefits of antidepressants in the treatment of depression and anxiety are due to the placebo response, and the difference in improvement between drug and placebo is not clinically meaningful and may be due to breaking blind by both patients and clinicians.
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
The differing levels of evidence that support the use of ADT based on Food and Drug Administration approvals, data from randomized controlled trials or meta-analyses are discussed and theoretical pharmacodynamic principles to justify antidepressant choice in the treatment of MDD patients are discussed.
Meta-analysis of the placebo response in antidepressant trials.
Clinical trials of antidepressant medications are producing meaningless results
Whether clinical trials for antidepressant medication produce meaningless results is discussed, as unipolar depression has jumped into the top five of the world's total burden of disease, and there is an imperative need for effective and safe treatments.
Efficacy of Antidepressants and USPSTF Guidelines for Depression Screening
  • R. Poses
  • Psychology, Medicine
    Annals of Internal Medicine
  • 2010
The efforts of the U.S. Preventive Service TaskForce (USPSTF) to keep their evidence-based guidelines up to dateare praiseworthy. It is understandable that practical concerns maylimit specific
The Food and Drug Administration’s Deliberations on Antidepressant Use in Pediatric Patients
It is concluded that there was a causal link between the newer antidepressants and pediatric suicidality and implications for care for children and adolescents who may be eligible for treatment with these medications.


Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication
Examination of pre–post effect sizes among depressed individuals assigned to no-treatment or wait-list control groups suggest that approximately one quarter of the drug response is due to the administration of an active medication, one half is a placebo effect, and the remaining quarter isdue to other nonspecific factors.
Drugs and Placebos: A Model Design
This srudy was planned to cest a model design for the analysis of drug effects on performance and mood measures in human Ss. It represents an extension of studies done previously with the population
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.
Assessment of suicides, suicide attempts, and depressive symptom reduction in studies of 7 new antidepressants using the Food and Drug Administration database may help inform discussions about the use of placebo in antidepressant clinical trials.
The Limits of Biological Treatments for Psychological Distress: Comparisons with Psychotherapy and Placebo
This book originated from a symposium of the American Psychiatric Association, and some of the chapters lack conciseness, as if prepared from scripts, and it was interesting to note that patients with seasonal affective disorder and summer depression have a high incidence of thyroid dis ease and cold treatment was used to treat one such person.
How Sound Is the Double-Blind Design for Evaluating Psychotropic Drugs?
The deficiencies of the double-blind paradigm call for a questioning stance with respect to previous studies of psychotropic drug efficacy, and various possible ways of strengthening the double blind paradigm are reviewed.
  • M. Hamilton
  • Psychology, Medicine
    Journal of neurology, neurosurgery, and psychiatry
  • 1960
The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information.
Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis.
A meta-analysis of research investigating the effects of alcohol consumption and expectancy within the balanced-placebo design found that both alcohol and expectancy have significant, although heterogeneous effects on behavior.
Recommendation for approvable action for Celexa (citalopram) for the treatment of depression. Memoradum: Department of Health and Human Services, Public Health Service, Food and Drug Administration
  • Recommendation for approvable action for Celexa (citalopram) for the treatment of depression. Memoradum: Department of Health and Human Services, Public Health Service, Food and Drug Administration
  • 1998